Meeting
2022 ASCO Annual Meeting
Circulating tumor DNA and recurrence risk in stage II-III gastric cancer.
Authors
Shu-Qiang Yuan
Sun Yat-sen University Cancer Center, Guangzhou, China
Shu-Qiang Yuan , You-Sheng Huang , Run-Cong Nie , Yingbo Chen , Si-Yu Wang , Xiaowei Sun , Yuanfang Li , Ze-Kun Liu , Yan-Xing Chen , Yi-Chen Yao , Yu Xu , Haibo Qiu , Yao Liang , Wei Wang , Zhiwei Zhou , Rui-hua Xu , Feng Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4054)
DOI
10.1200/JCO.2022.40.16_suppl.4054
Abstract #
4054
Poster Bd #
42
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
First Author: Yuichiro Tsukada
Poster
2024 ASCO Annual Meeting
Individualized tumor-informed circulating tumor DNA analysis for molecular residual disease detection in predicting recurrence and efficacy of adjuvant chemotherapy in colorectal cancer.
First Author: Di Cao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial).
First Author: Hiroyuki Arai
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.
First Author: Noelia Tarazona